Full Press Release Details
Rule 2.7, 3.10.3, 3.10.4, 3.10.5
application for quotation of additional securities
Information or documents
not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX s property and may be made public.
Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.
We (the entity) give ASX the following information.
You must complete the relevant sections (attach sheets if there is not enough space).
| 1 + Class of + securities issued or to be issued | 1. Unlisted Performance Rights | |||
| 2. Ordinary Shares | ||||
| 2 Number of + securities issued or to be issued (if known) or maximum number which may be issued | 1. 10,000,000 Unlisted Performance Rights | |||
| 2. 3,900,000 Ordinary Shares |
| 3 Principal terms of the + securities (e.g., if options, exercise price and expiry date; if partly paid + securities, the amount outstanding and due dates for payment; if + convertible securities, the conversion price and dates for conversion) | 1. Unlisted Performance Rights | |||||||
| Number of performance rights | 10,000,000. This number has been calculated based on 4 years of directors fees at $60,000 per annum divided by $0.024 (being the 5 day VWAP up to and including 15 December 2017). | |||||||
| Vesting conditions | Service-based vesting conditions only. | |||||||
| Tranche 1 | 2,500,000 on 1 December 2018. (Being continued service from 18 November 2017 to 17 November 2018 | |||||||
| Tranche 2 | 2,500,000 on 1 December 2019. (Being continued service from 18 November 2018 to 17 November 2019 | |||||||
| Tranche 3 | 2,500,000 on 1 December 2020. (Being continued service from 18 November 2019 to 17 November 2020 | |||||||
| Tranche 4 | 2,500,000 on 1 December 2021. (Being continued service from 18 November 2020 to 17 November 2021 | |||||||
| Expiry Date | The performance rights will expire, if not exercised, one year after the relevant vesting date for each tranche of performance rights (see above) | |||||||
| Price of performance rights | Performance rights will be granted at no cost. Once the vesting conditions (service only) are met (or waived in exceptional circumstances), the performance rights will be exercisable at nil cost. | |||||||
| 2. Pari passu with existing Fully Paid Ordinary Shares | ||||||||
| 4 Do the + securities rank equally in all respects from the date of allotment with an existing + class of quoted + securities? If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | 1. Yes, if/when the Performance Rights vest to shares 2. Pari Passu with existing Fully Paid Ordinary Shares |
| 5 Issue price or consideration | 1. Nil 2. Nil | |||
| 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) | 1. Unlisted Performance Rights are issued to Dr Russell Howard in lieu of cash for his services as a non-executive director, in accordance with shareholder approval at the AGM held on 16 November 2018. 2. Vesting & exercise of Performance Rights under the Executive Incentive Plan into fully paid ordinary shares. | |||
| 6a Is the entity an + eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b 6h in relation to the + securities the subject of this Appendix 3B , and comply with section 6i | Yes | |||
| 6b The date the security holder resolution under rule 7.1A was passed | 16 November 2018 | |||
| 6c Number of + securities issued without security holder approval under rule 7.1 | Nil | |||
| 6d Number of + securities issued with security holder approval under rule 7.1A | Nil | |||
| 6e Number of + securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) | 1. 10,000,000 performance rights approved at the AGM on 16 November 2018 for Non-Executive Director, Dr Russell Howard. | |||
| 6f Number of + securities issued under an exception in rule 7.2 | 2. 3,900,000 issued under exception 4 in rule 7.2 |
| 6g If + securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the + issue date and both values. Include the source of the VWAP calculation. | Not applicable | |||||||
| 6h If + securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements | Not applicable | |||||||
| 6i Calculate the entity s remaining issue capacity under rule 7.1 and rule 7.1A complete Annexure 1 and release to ASX Market Announcements | Refer Annexure 1 | |||||||
| 7 + Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B. | 21 November, 2018 | |||||||
| Number | + Class | |||||||
| 8 Number and + class of all + securities quoted on ASX ( including the securities in clause 2 if applicable) | 3,084,431,629 | Ordinary fully paid shares (ASX: IMM) | ||||||
| Number | + Class - Options | |||||||
| 9 Number and + class of all + securities not quoted on the ASX (including the securities in clause 2 if applicable) | Amount | Exercise Price | Expiration Date | |||||
| 147,628,500 | $0.05019 | 12 December 2018 | ||||||
| 371,445,231 | $0.0237 | 4 August 2020 | ||||||
| 793,103 | $0.057 | 30 October 2020 | ||||||
| 1,026,272 | $0.040 | 7 March 2021 | ||||||
| 8,475,995 | $0.025 | 4 August 2025 |
| Number | + Class Warrants over NASDAQ listed American Depository Shares | |||||||
| Amount | Exercise Price | Terms | ||||||
| 1,553,718 | US$2.50 | Each Warrant entitles the holder to purchase 1 ADS (where one ADS = 100 Ordinary Shares) at the exercise price and is exercisable immediately. Each Warrant will expire 5 January 2023 | ||||||
| Number | + Class Performance Rights | |||||||
| Amount | Type | Expiration Date | ||||||
| 5,472,734 | NED PRs | Each tranche of NED PRs will expire one year after Vesting Date if not exercised as indicated in the appendix 3B released on 6 December 2016. | ||||||
| 8,533,063 | NED PRs | Each tranche of NED PRs will expire one year after Vesting Date if not exercised as indicated in this appendix 3B released on 4December 2017 | ||||||
| 73,333,333 | LTI | Each tranche of LTIs will expire one year after Vesting Date if not exercised as indicated in this appendix 3B released on 4 December 2017 | ||||||
| 10,000,000 | LTI | Each tranche of LTIs will expire one year after Vesting Date if not exercised as indicated in this appendix 3B released on 4 December 2017 | ||||||
| 7,751,152 | LTI | Each tranche of LTIs will expire one year after Vesting Date if not exercised as indicated in this appendix 3B released on 2 October 2018 | ||||||
| 10,000,000 | NED PRs | Each tranche of NED PRs will expire one year after Vesting Date if not exercised as indicated in the appendix 3B released on 21 November 2018. | ||||||
| Number | + Class Convertible Notes | |||||||
| Amount | Type | Expiration Date | ||||||
| 13,750,828 | Convertible Notes each with a face value of AU$1, expiring on 4 August 2025 |
Part 2 - Bonus issue or pro rata issue
| 11 Is security holder approval required? | Not applicable | |||
| 12 Is the issue renounceable or non-renounceable? | Not applicable | |||
| 13 Ratio in which the + securities will be offered | Not applicable | |||
| 14 + Class of + securities to which the offer relates | Not applicable | |||
| 15 + Record date to determine entitlements | Not applicable | |||
| 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? | Not applicable | |||
| 17 Policy for deciding entitlements in relation to fractions | Not applicable | |||
| 18 Names of countries in which the entity has + security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. | Not applicable | |||
| 19 Closing date for receipt of acceptances or renunciations | Not applicable | |||
| 20 Names of any underwriters | Not applicable |
| 21 Amount of any underwriting fee or commission | Not applicable | |||
| 22 Names of any brokers to the issue | Not applicable | |||
| 23 Fee or commission payable to the broker to the issue | Not applicable | |||
| 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of + security holders | Not applicable | |||
| 25 If the issue is contingent on + security holders approval, the date of the meeting | Not applicable | |||
| 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled | Not applicable | |||
| 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | Not applicable | |||
| 28 Date rights trading will begin (if applicable) | Not applicable | |||
| 29 Date rights trading will end (if applicable) | Not applicable | |||
| 30 How do + security holders sell their entitlements in full through a broker? | Not applicable | |||
| 31 How do + security holders sell part of their entitlements through a broker and accept for the balance? | Not applicable |
| 32 How do + security holders dispose of their entitlements (except by sale through a broker)? | Not applicable | |||
| 33 + Despatch date | Not applicable |
Part 3 - Quotation of securities
You need only complete this section if you are applying for quotation of securities
Entities that have ticked box 34(a)
securities forming a new class of securities
Tick to indicate you are providing the information or documents
| 38 Number of securities for which + quotation is sought | Not applicable | |||||
| 39 Class of + securities for which quotation is sought | Not applicable | |||||
| 40 Do the + securities rank equally in all respects from the date of allotment with an existing + class of quoted + securities? If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | Not applicable | |||||
| 41 Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security) | Not applicable | |||||
| Number | + Class | |||||
| 42 Number and + class of all + securities quoted on ASX ( including the securities in clause 38) | Not applicable |
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this
| Sign here: | ........................................................................... | Date: 21/11/2018 | ||
| Company secretary | ||||
| Print name: | Deanne Miller |
Appendix 3B Annexure 1
Calculation of placement capacity under
rule 7.1 and rule 7.1A for eligible entities
Introduced 01/08/12 Amended 04/03/13
| Rule 7.1 Issues exceeding 15% of capital | ||
| Step 1: Calculate A , the base figure from which the placement capacity is calculated | ||
| Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue | 2,362,662,532 | |
| Add the following: Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval Number of partly paid +ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | 721,769,097 | |
| Subtract the number of fully paid +ordinary securities cancelled during that 12 month period | Nil | |
| A | 3,084,431,629 |
| Step 2: Calculate 15% of A | ||
| B | 0.15 [Note: this value cannot be changed] | |
| Multiply A by 0.15 | 462,664,744 | |
| Step 3: Calculate C , the amount of placement capacity under rule 7.1 that has already been used | ||
| Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued: Under an exception in rule 7.2 Under rule 7.1A With security holder approval under rule 7.1 or rule 7.4 Note: This applies to equity securities, unless specifically excluded not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | Nil | |
| C | Nil | |
| Step 4: Subtract C from [ A x B ] to calculate remaining placement capacity under rule 7.1 | ||
| A x 0.15 Note: number must be same as shown in Step 2 | 462,664,744 | |
| Subtract C Note: number must be same as shown in Step 3 | Nil | |
| Total [ A x 0.15] C | 462,664,744 Note: this is the remaining placement capacity under rule 7.1 |
| Rule 7.1A Additional placement capacity for eligible entities | ||
| Step 1: Calculate A , the base figure from which the placement capacity is calculated | ||
| A Note: number must be same as shown in Step 1 of Part 1 | 3,084,431,629 | |
| Step 2: Calculate 10% of A | ||
| D | 0.10 Note: this value cannot be changed | |
| Multiply A by 0.10 | 308,443,162 | |
| Step 3: Calculate E , the amount of placement capacity under rule 7.1A that has already been used | ||
| Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities not just ordinary securities Include here if applicable the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items | Nil | |
| E | 308,443,162 |
| Step 4: Subtract E from [ A x D ] to calculate remaining placement capacity under rule 7.1A | ||
| A x 0.10 Note: number must be same as shown in Step 2 | 308,443,162 | |
| Subtract E Note: number must be same as shown in Step 3 | Nil | |
| Total [ A x 0.10] E | 308,443,162 Note: this is the remaining placement capacity under rule 7.1A |